Synagis
Synagis Brand names, Synagis Analogs
Synagis Brand Names Mixture
- No information avaliable
Synagis Chemical_Formula
No information avaliable
Synagis RX_link
http://www.rxlist.com/cgi/generic2/palivizumab.htm
Synagis fda sheet
Synagis msds (material safety sheet)
Synagis Synthesis Reference
sequence listed in Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24.
Synagis Molecular Weight
No information avaliable
Synagis Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Synagis H2O Solubility
No information avaliable
Synagis State
Liquid
Synagis LogP
No information avaliable
Synagis Dosage Forms
Powder for solution
Synagis Indication
For treatment of respiratory diseases casued by respiratory syncytial virus
Synagis Pharmacology
Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.
Synagis Absorption
No information avaliable
Synagis side effects and Toxicity
No information avaliable
Synagis Patient Information
No information avaliable
Synagis Organisms Affected
No information avaliable
